From Denver to Helsinki: PAREA celebrates its third birthday at the European Academy of Neurology Congress 2025!
Just days after presenting in Denver, the PAREA team travelled to Helsinki to participate in the European Academy of Neurology (EAN) Congress, a major event that also marked PAREA’s three-year anniversary.
Our presence in the Neurohood exhibition area sparked rich dialogue with clinicians, researchers, and patient advocates—many of whom were seeing, for the first time, the full scope of neurology-related psychedelic trials visualised in a striking bull’s eye graphic, courtesy of Psychedelic Alpha.
As part of the EAN’s Scientific Theatre, we presented the PsyPal trial—the first EU-funded clinical trial of psilocybin-assisted therapy, targeting four life-limiting conditions, including three neurological diagnoses: amyotrophic lateral sclerosis, multiple sclerosis, and atypical Parkinson’s.
We were especially pleased to connect in person with key figures shaping brain health policy and advocacy in Europe and beyond, including:
Elena Moro, President, European Academy of Neurology (EAN)
Wolfgang Grisold, President, World Federation of Neurology (WFN)
William Carroll, Past President, WFN
Tasia Akasawa, Executive Director, Federation of Neurological Associations (FENS)
Joke Jaarsma, Past President, European Federation of Neurological Associations (EFNA)
Orla Galvin, Executive Director, EFNA
Nadia Malliou, Executive Director, Pain Alliance Europe (PAE)
The EAN Congress provided an important platform to expand awareness about psychedelic science within the neurology community, reaffirming the importance of collaboration across disciplines and sectors. Celebrating three years of PAREA amid such vibrant scientific exchange was a perfect reminder of why we do this work—and how far the conversation has come.
